Fig. 7
SST14 and cyclosomatostatin fail to affect pharmacologically isolated non-NMDAR-mediated EPSCs. a, b Voltage clamp recording of EPSCs (top) and time plots of EPSC amplitude from representative SOM-INs receiving 5 µM SST14 (a) or vehicle (b). EPSCs shown are average for -5 to 0 min baseline period (pre) and 30 to 35 min post-application period (post). c Summary time plots of EPSCs (normalized to baseline), showing lack of lasting effects on EPSC amplitude after SST14 application (filled green circle) or vehicle application (open green circle) (vehicle, n = 11 cells and 7 mice; SST14, n = 10 cells and 6 mice; two-way mixed ANOVA p = 0.485). d, e EPSCs (top) and time plots of EPSC amplitude from representative SOM-INs receiving TBS in the presence of DMSO (d) or 1 µM cyclosomatostatin (e). EPSCs shown are average for − 10 to 0 min baseline period (pre) and 25 to 30 min post-TBS period (post). f Summary time plots of EPSCs (normalized to baseline), showing similar LTP of EPSC amplitude induced by TBS in DMSO (filled blue circle) and cyclosomatostatin (open blue circle). For DMSO group, n = 9 cells and 7 mice, Two-way mixed ANOVA p = 0.402, main effect of time p < 0.0001 with Bonferroni’s multiple comparisons at 20–25 min p = 0.019, 25–30 min p = 0.017). g Summary bar graph showing no difference in EPSC amplitude at 30–35 min after SST14 or vehicle application (left), and increase in EPSC amplitude at 25–30 min after TBS showing similar LTP in DMSO and cyclosomatostatin (right). * p < 0.05; ns: no significant